Cardiovascular prevention in peri- and postmenopausal women

• Main Authors: N. A. Voychenko, I. V. Kuznetsova, V. B. Mychka, M. Yu. Kirillova, S. N. Tolstov
• Format: Article
• Language: Russian
• Published: «SILICEA-POLIGRAF» LLC 2011-06-01
• Series: Кардиоваскулярная терапия и профилактика
• Subjects: metabolic syndrome; menopause; renin-angiotensin-aldosterone system; arterial hypertension; obesity; hormone replacement therapy; drospirenone
• Online Access: https://cardiovascular.elpub.ru/jour/article/view/1845

The adverse consequences of estrogen deficiency in postmenopause include cardiovascular disease (CVD), which affects not only women’s quality of life, but also their life expectancy. Before premenopause, women have significantly lower risk of arterial hypertension than men of the same age. However, in people aged over 50, AH is more prevalent among women. Currently, most experts regard hormone replacement therapy (HRT) in peri- and postmenopausal women as pathogenetic, since it facilitates the adaptation of the female organism to the new metabolic state, with reduced ovarian function. Drospirenone, as a part of HRT, reduces CVD risk in postmenopausal women with climacteric disturbances.